NCT06259526
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Tasly Pharmaceutical Group Co., Ltd·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Depression
- Drug/Device/Intervention
- Placebo group
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Location
- Beijing,Peking,Chongqing,Chongqing,Guangzhou,Baoding,Shijiazhuang,Daqing,Wuxi,Zhenjiang,Nanchang,Siping,Jinan,Tianjin,Ürümqi,Kunming,Huzhou, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Dec 26, 2023
- End date
- Apr 26, 2025
- Enrollment
- 260 participants
Primary outcome
The change in MADRS total score from baseline
Summary
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients
 With Moderate to Severe Depression
ICD-10 classifications
Depressive episodeOther depressive episodesRecurrent depressive disorderRecurrent depressive disorder, unspecifiedPost-schizophrenic depression
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06259526
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06259526 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Recruiting. The study focuses on Depression. Target enrollment is 260 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.